Syngene Reports FY26 Revenue Up 3% as Margins Slip to 25%

Syngene posted modest top‑line growth in FY26 but saw margin compression and a sharp PAT decline, while dramatically cutting debt and reshaping its leadership team.

• Revenue rose 3% YoY to Rs 3,739 cr for the year (Q4 up 2% to Rs 1,037 cr).
• Operating EBITDA margin slipped to 25% from 29% FY25; PAT (before exceptional items) fell 20% to Rs 380 cr. Cash generated from operations was Rs 521 cr, and a final dividend of Rs 1.25 per share was recommended.
• Leadership changes: Kiran Mazumdar‑Shaw became Executive Chairperson (5‑year term), Siddharth Mittal appointed MD & CEO (effective 1 Jul 2026), plus two new independent directors and senior hires from Biocon as CHRO and CCO.
• Balance sheet: total assets rose to Rs 70,547 mn, cash & equivalents fell to Rs 2,286 mn, but borrowings were slashed to Rs 94 mn from Rs 1,196 mn, while current liabilities increased to Rs 15,523 mn.
• Strategic push on ADC discovery labs, AI‑driven digital services, and ESG leadership (top‑10 in S&P Global Sustainability Yearbook 2026), offset by risks of margin pressure, higher staff costs, and client concentration.